We discuss a 30-Month Outcome with Pegcetacoplan for the Treatment of Geographic Atrophy with Nathan Steinle MD, California Retina Consultants, Santa Barbara, California.

We discuss the latest information on Safety & Efficacy in Clinic and Clinical Trials with Cedric Francois, MD, PhD.

We discuss the latest information on the use of faricimab in neovascular AMD with Dr. Yasha Modi, Associate Professor of Ophthalmology, NYU Langone Medical Center.

We discuss the use of high dose aflibercept for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor, Roski Eye Institute of USC.

We discuss the latest information on the use of pegcetacoplan for geographic atrophy in AMD with Dr. Dilsher Dhoot, California Retinal Consultants.

We discuss the use of a novel drug (tyrosine kinase inhibitor) and novel delivery system (hydrogel) for the treatment of neovascular AMD with Dr. Peter Kaiser of the Cleveland Clinic.

We discuss the use of biosimilar drugs for retinal diseases with Dr. Arghavan Almony, author of definitive monograph of these agents.

In our latest update, we discuss the relative drying effects of faricimab and aflibercept in the treatment of diabetic macular edema with Dr. Roger Goldberg.

In our latest update, we discuss the use of artificial intelligence in the management of geographic atrophy with Professor Pearse Keane, Moorfields Eye Hospital, London.

In our latest update, we discuss the use of molecular techniques in the management of uveal melanoma with Dr. William Harbour, Professor and Chair, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.